Interview: Why Europe’s Biotech ‘Prime Time’ Is Now
VC Firm Sofinnova’s Chair Papiernik Speaks After New Fund Launch
The chairman of Sofinnova Partners told Scrip his newly launched biotech start-up fund aims to profit from Europe’s top science, relatively realistic asset prices, and geopolitical position between the US and China.
You may also be interested in...
As once-star investment funds fail, another major investor argues this is opportunity for UK biotech to demonstrate staying power.
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.
Incyte welcomed FDA approval of its ruxolitinib cream, a selective JAK1/JAK2 inhibitor, as a treatment for atopic dermatitis, but criticized the boxed warnings label assigned to it.